Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer
Crossref DOI link: https://doi.org/10.1007/s00280-014-2625-3
Published Online: 2014-12-02
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hochster, H. S.
Uboha, N.
Messersmith, W.
Gold, P. J.
ONeil, B. H.
Cohen, D.
Denlinger, C.
Cohen, S.
Leichman, C. G.
Leichman, L.
Lenz, H.-J.
Text and Data Mining valid from 2014-12-02